Allergen immunotherapy with nanoparticles containing lipopolysaccharide from Brucella ovis
Sara Gómez (a), Carlos Gamazo (a), Beatriz San Roman (a), Marta Ferrer (b), Maria Luisa Sanz (b), Socorro Espuelas (a) and Juan M. Irache (a)
(a) Departments of Pharmaceutical Technology and Microbiology, University of Navarra, Pamplona, Spain
(b) Allergy Department, University Hospital of Navarra, Pamplona, Spain
The adjuvant and protective capacity against anaphylactic shock of the association between rough lipopolysaccharide of Brucella ovis (LPS) coencapsulated with ovalbumin (OVA), as a model allergen, in Gantrez AN nanoparticles was investigated.
Several strategies were performed in order to study the adjuvant effect of the LPS either encapsulated or coating the nanoparticles. OVA, as well as LPS, was incorporated either during the manufacturing process (OVA-encapsulated or LPS-encapsulated nanoparticles, respectively) or after the preparation (OVA-coated or LPS-coated nanoparticles, respectively).
After the administration of 10 microg of OVA incorporated in the different formulations, all the nanoparticles, with or without LPS, were capable of amplifying the immune response (IgG(1) and IgG(2a)). However, in a model of sensitized mice to OVA, the formulation with OVA and LPS-entrapped inside the nanoparticles administered intradermally in three doses of 3 microg of OVA each was the only treatment that totally protected the mice from death after a challenge with an intraperitoneal injection of OVA. In contrast, the control group administered with OVA adsorbed onto a commercial alhydrogel adjuvant showed 80% mortality.
These results are highly suggestive for the valuable use of Gantrez nanoparticles combined with rough LPS of B. ovis in immunotherapy.
CITATION Eur J Pharm Biopharm. 2008 Nov;70(3):711-7